BriaCell Therapeutics Corp.

BCT

CA1079303071

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 03:49:30 2026-07-17 pm EDT			5-day change	1st Jan Change
5.260 ^CAD	-1.50%		-5.73%	-46.33%

Jul. 16	BriaCell Opens First Canadian Site For Phase 3 Metastatic Breast Cancer Study	MT
Jul. 16	BriaCell Therapeutics Corp. Opens First Canadian Site For Pivotal Phase 3 Trial In Metastatic Breast Cancer	CI

Top Midday Decliners

Published on 01/14/2026 at 02:11 pm EST

MT Newswires

Add MarketScreener to your sources

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Add MarketScreener to your sources

Latest news about BriaCell Therapeutics Corp.

Jul. 16	BriaCell Opens First Canadian Site For Phase 3 Metastatic Breast Cancer Study	MT
Jul. 16	BriaCell Therapeutics Corp. Opens First Canadian Site For Pivotal Phase 3 Trial In Metastatic Breast Cancer	CI
Jul. 07	BriaCell Engages Consulting and Branding Firms to Support Potential Commercialization of Bria-IMT	MT
Jun. 25	BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT	CI
Jun. 25	BriaCell Therapeutics Inks MOU With Dutch Microneedle Company	MT
Jun. 09	BriaCell Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2026	CI
Jun. 02	BriaCell Therapeutics Rises After Hours as It Closes a $4.7-Million Share Offering	MT
Jun. 02	BriaCell Therapeutics Closes $4.7 Million Share Offering	MT
Jun. 01	BriaCell Presenting Final Phase 2, Ongoing Phase 3 Data at ASCO Meeting	MT
Jun. 01	BriaCell Down 9.3% as Prices Offering to Raise US$4.7 Million	MT
Jun. 01	BriaCell Therapeutics Prices $4.7 Million Share Offering	MT
May. 31	Briacell Therapeutics prices 1.45 million common shares at $3.25 per share	RE
May. 26	Briacell Therapeutics Corp. Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study of Bria-Imt Plus Immune Checkpoint Inhibitor in Metastatic Breast Cancer	CI
May. 26	BriaCell Receives DSMB Nod to Continue With Phase 3 Metastatic Breast Cancer Study	MT
May. 26	BriaCell Says Received Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer	MT

Chart BriaCell Therapeutics Corp.

Duration

Period

BCT: Dynamic Chart

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patientâ€™s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.

Employees

Sector

Biotechnology & Medical Research

More about the company